This episode explores the controversial role of pimavanserin in treating psychosis in Parkinson's disease. How does it compare with quetiapine or clozapine? Sneak peek: All of these medications are effective, yet none distinctly surpasses the others. Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 51 Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis 

Pimavanserin: A Solution for Psychosis in Parkinson's Disease?

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health & Fitness

In this episode, we discuss the management of common adverse effects associated with clozapine treatment, including myocarditis, cardiomyopathy, tachycardia, orthostatic hypotension, and metabolic syndrome. How can clinicians mitigate these risks while optimizing treatment outcomes for patients with treatment-resistant schizophrenia?  Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 1.25 CME: Clozapine: Management and Challenges Managing Cardiac and Metabolic Adverse Effects of Clozapine 

Mastering Clozapine: Adverse Effect Management

In this episode, we explore relapse prevention strategies for youth with depression and anxiety disorders. Are there effective ways to reduce the risk and prolong the time to relapse? Dr. David Rosenberg discusses the findings of a recent meta-analysis and systematic review on this crucial topic. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 15 Relapse Prevention Strategies for Depression and Anxiety in Remitted Youth 

Preventing Depression and Anxiety Relapse in Youth

In this episode, we navigate the complexities of initiating and optimizing clozapine treatment for patients with treatment-resistant schizophrenia. How do you chart the course for successful clozapine therapy while managing side effects and drug interactions? Join us as Dr. Brian Miller shares his expertise and valuable psychopharmacology pearls. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 1.25 CMEs: Clozapine: Management and Challenges Initiating and Optimizing Clozapine 

Charting the Clozapine Course: Titration and Monitoring

In this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.  Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 55 Tobacco Use, Nicotine Dependence, and Cessation Among Adults with Psychosis 

Smoking and Psychosis: Insights from the PATH Study

In this episode, we delve into the use of clozapine for treatment-resistant psychosis and mood disorders. When should clinicians consider clozapine, and what do expert guidelines recommend? Dr. Brian Miller guides us through the evidence and best practices for utilizing this powerful but often underused medication. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D.  Learn more about our memberships here Earn 1.25 CME: Clozapine: Management and Challenges Using Clozapine for Treatment-Resistant Psychosis and Mood Disorders 

Pimavanserin: A Solution for Psychosis in Parkinson's Disease?

Download our free app to listen on your phone